World's Best Scientists 2026 revealed!
Animesh Pardanani

Animesh Pardanani

D-Index & Metrics

Medicine

D-Index
111
Citations
47996
World Ranking
5316
National Ranking
2869

Animesh Pardanani publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Animesh Pardanani sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 755 publications — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Animesh Pardanani D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Animesh Pardanani sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 111 D-Index — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Animesh Pardanani is affiliated with the Mayo Clinic in the United States and has contributed extensively to the field of medical research, with a particular focus on hematology. Their body of work encompasses a wide range of topics primarily related to hematological disorders and malignancies.

Their research is prominently featured in several high-impact publication venues. Frequent journals where their work appears include:

  • Blood
  • American Journal of Hematology
  • Blood Cancer Journal
  • Haematologica
  • British Journal of Haematology

Their main field of study is Medicine, with a strong emphasis on several subfields:

  • Hematology
  • Genetics
  • Molecular Biology
  • Rheumatology
  • Immunology

Animesh Pardanani's research addresses numerous key topics, including:

  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Eosinophilic Disorders and Syndromes
  • Kruppel-like factors research
  • Hemoglobinopathies and Related Disorders
  • Mast cells and histamine

The scientist has collaborated frequently with several researchers, including:

  • Ayalew Tefferi
  • Naseema Gangat
  • Mrinal M. Patnaik
  • Aref Al-Kali
  • Kebede H. Begna

Some notable recent publications authored or co-authored by Animesh Pardanani include:

  • Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management, 2023, American Journal of Hematology
  • Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management, 2021, American Journal of Hematology
  • Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera, 2020, British Journal of Haematology
  • Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients, 2020, American Journal of Hematology (co-authored)
  • Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network (co-authored)

This profile underscores Animesh Pardanani's involvement in advancing understanding and clinical approaches within blood cancers and related hematological conditions through prolific research contributions combined with extensive collaboration in the field.

Best Publications

  • Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

    Srdan Verstovsek;Hagop Kantarjian;Ruben A. Mesa;Animesh D. Pardanani

  • MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

    Animesh D. Pardanani;Ross L. Levine;Terra Lasho;Yana Pikman

  • DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

    Naseema Gangat;Domenica Caramazza;Rakhee Vaidya;Geeta George

  • Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

    Tiziano Barbui;Giovanni Barosi;Gunnar Birgegard;Francisco Cervantes

  • Mutations and prognosis in primary myelofibrosis

    Alessandro Maria Vannucchi;Tl Lasho;Paola Guglielmelli;Flavia Biamonte

  • Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study

    A Tefferi;E Rumi;G Finazzi;H Gisslinger

  • Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis

    Ayalew Tefferi;Paola Guglielmelli;Dirk R. Larson;Christy Finke

  • Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

    Ross L. Levine;Animesh Pardanani;Ayalew Tefferi;D. Gary Gilliland

  • Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors

    Ken Hong Lim;Ayalew Tefferi;Terra L. Lasho;Christy Finke

  • CALR vs JAK2 vs MPL -mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

    A Tefferi;T L Lasho;C M Finke;R A Knudson

  • Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

    Ayalew Tefferi;Rakhee Vaidya;Rakhee Vaidya;Domenica Caramazza;Domenica Caramazza;Christy Finke;Christy Finke

  • TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

    A. Tefferi;A. Pardanani;K. H. Lim;K. H. Lim;O. Abdel-Wahab

  • MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

    Paola Guglielmelli;Terra L. Lasho;Giada Rotunno;Mythri Mudireddy

  • Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

    Animesh Pardanani;Jason R. Gotlib;Catriona Jamieson;Jorge E. Cortes

  • Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.

    Animesh Pardanani;Claire Harrison;Jorge E. Cortes;Francisco Cervantes

  • CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

    Animesh Pardanani;Animesh Pardanani;Animesh Pardanani;Rhett P. Ketterling;Rhett P. Ketterling;Rhett P. Ketterling;Stephanie R. Brockman;Stephanie R. Brockman;Stephanie R. Brockman;Heather C. Flynn;Heather C. Flynn;Heather C. Flynn

  • Treatment of hypereosinophilic syndrome with imatinib mesilate

    Gerald J Gleich;Kristin M Leiferman;Animesh Pardanani;Ayalew Tefferi

  • Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

    Ayalew Tefferi;Francisco Cervantes;Ruben Mesa;Francesco Passamonti

  • FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.

    Animesh Pardanani;Stephanie R. Brockman;Sarah F. Paternoster;Heather C. Flynn

  • A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

    Ruben A. Mesa;David P. Steensma;David P. Steensma;Animesh Pardanani;Animesh Pardanani;Chin Yang Li;Chin Yang Li

Frequent Co-Authors

Ayalew Tefferi
Ayalew Tefferi Mayo Clinic
Terra L. Lasho
Terra L. Lasho Mayo Clinic
Curtis A. Hanson
Curtis A. Hanson Mayo Clinic
Mark R. Litzow
Mark R. Litzow Mayo Clinic
Ruben A. Mesa
Ruben A. Mesa The University of Texas Health Science Center at San Antonio
Alessandro M. Vannucchi
Alessandro M. Vannucchi University of Florence
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Paola Guglielmelli
Paola Guglielmelli University of Florence

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA is a significant commitment, but there are several related online degrees and pathways that can enable a healthcare career or specialization. Many students consider direct-entry options when transitioning into nursing or advancing their practice. For those interested in a streamlined path, direct entry nursing programs can be an efficient choice, especially for those with a non-nursing background.

If you want to become a registered nurse, another accessible pathway is the direct entry msn programs online, offering a faster route to advanced nursing roles even for non-nurses. For practicing nurses aiming to elevate their credentials, understanding the average cost of rn to bsn programs is essential, as affordability can vary widely.

For advanced research or academic positions, online doctoral options are increasingly popular. Many choose phd in nursing online programs that offer flexibility for working professionals. Exploring these various online pathways can help students find the best route for their goals while managing costs and timelines.

Best Scientists Citing Animesh Pardanani

Trending Scientists

Recently Published Articles